Mesoporous Carbon Nanoparticles
The study of mesoporous carbon nanoparticles (MCN) as an option for the administration of sustained drug delivery and targeted therapy presents a compelling prospect in the realm of Alzheimer’s Disease (AD) treatment129. In their study, Xu et al. provided evidence supporting the therapeutic efficacy of oxidized mesoporous carbon nanoparticles (MCN) loaded with PX (a specific drug) and functionalized with RVG peptides in the context of Alzheimer’s disease (AD)130. Protoporphyrin IX (PX) emerges as a compelling contender for the treatment of Alzheimer’s disease (AD) due to its capacity to mitigate tau phosphorylation while exhibiting a notable absence of deleterious toxicological ramifications. Nevertheless, the therapeutic efficacy of the substance is constrained due to its incapacity to traverse the blood-brain barrier (BBB).
The modifications made to the RVG (rabies virus glycoprotein) on the MCN (magnetic carbon nanotube) surfaces have been observed to enhance the ability of these nanotubes to penetrate the blood-brain barrier (BBB)130. This conclusion is supported by both in vitro (performed in a controlled laboratory setting) and in vivo (conducted in living organisms) studies. Furthermore, the utilization of ultrasound radiation was employed as a means to accomplish precise and targeted drug delivery within the intricate confines of the human brain. The in vitro investigations have substantiated the presence of crucial attributes in the synthesized PX-MCN-RVG nanoparticles, including their capacity for accumulation, biocompatibility, minimal immunogenicity, and absence of cytotoxic effects. These findings establish the potential efficacy of these nanoparticles for therapeutic applications.
The combination of PX-MCN-RVG nanoparticles (NPs) with ultrasound therapy has demonstrated encouraging outcomes in the context of inhibiting amyloid-beta monomer aggregation by approximately 71% and impeding amyloid-beta mediated apoptosis in an in vitro setting. Furthermore, the NPs that were formulated demonstrated effective inhibition of GSK3β-mediated tau phosphorylation, which is a crucial mechanism involved in the pathogenesis of Alzheimer’s disease (AD).The efficacy of PX-MCN-RVG NPs in the treatment of Alzheimer’s disease (AD) has been substantiated through in vivo studies. These investigations have demonstrated the NPs’ capacity to impede the progression of the disease and enhance cognitive functions. This study elucidates the inherent capabilities of mesoporous carbon nanoparticles as a versatile framework for the integration of synergy therapies and the precise administration of therapeutic agents, thereby presenting a groundbreaking avenue for mitigating the symptoms associated with Alzheimer’s disease (AD) and laying the groundwork for future progressions in the realm of AD treatment methodologies130.